S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
The top-rated strong-buy stocks on Marketbeat’s radar
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Marketbeat’s AI-powered tools for investors
Are blue chip stocks a good investment?
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
As Dollar Tree Goes, So Goes the Consumer?
Power Play: GE's game-changing technology for EVs and grids
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Is Beyond an overlooked e-commerce winner?
Inflation in Europe falls to 2.4% as interest rates pack a punch. But the economy has stalled
S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
The top-rated strong-buy stocks on Marketbeat’s radar
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Marketbeat’s AI-powered tools for investors
Are blue chip stocks a good investment?
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
As Dollar Tree Goes, So Goes the Consumer?
Power Play: GE's game-changing technology for EVs and grids
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Is Beyond an overlooked e-commerce winner?
Inflation in Europe falls to 2.4% as interest rates pack a punch. But the economy has stalled
S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
The top-rated strong-buy stocks on Marketbeat’s radar
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Marketbeat’s AI-powered tools for investors
Are blue chip stocks a good investment?
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
As Dollar Tree Goes, So Goes the Consumer?
Power Play: GE's game-changing technology for EVs and grids
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Is Beyond an overlooked e-commerce winner?
Inflation in Europe falls to 2.4% as interest rates pack a punch. But the economy has stalled
S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
The top-rated strong-buy stocks on Marketbeat’s radar
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Marketbeat’s AI-powered tools for investors
Are blue chip stocks a good investment?
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
As Dollar Tree Goes, So Goes the Consumer?
Power Play: GE's game-changing technology for EVs and grids
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Is Beyond an overlooked e-commerce winner?
Inflation in Europe falls to 2.4% as interest rates pack a punch. But the economy has stalled

Charles River Laboratories International Stock Price, News & Analysis (NYSE:CRL)

$197.08
-0.02 (-0.01%)
(As of 11/30/2023 ET)
Compare
Today's Range
$194.67
▼
$199.05
50-Day Range
$164.53
▼
$199.62
52-Week Range
$161.65
▼
$262.00
Volume
402,407 shs
Average Volume
524,894 shs
Market Capitalization
$10.10 billion
P/E Ratio
21.33
Dividend Yield
N/A
Price Target
$232.54
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability

Charles River Laboratories International MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.64 Rating Score
Upside/​Downside
18.0% Upside
$232.54 Price Target
Short Interest
Healthy
3.18% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.55
Upright™ Environmental Score
News Sentiment
0.00mentions of Charles River Laboratories International in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$1.25 M Bought Last Quarter
Proj. Earnings Growth
3.88%
From $10.57 to $10.98 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.69 out of 5 stars

Medical Sector

81st out of 949 stocks

Diagnostics & Research Industry

1st out of 3 stocks

See Top Rated MarketRank™ Stocks Here

CRL stock logo

About Charles River Laboratories International Stock (NYSE:CRL)

Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

CRL Stock Price History

CRL Stock News Headlines

November 27, 2023 | finance.yahoo.com
Charles River Laboratories to Present at Evercore ISI Investor Conference
November 17, 2023 | finance.yahoo.com
Charles River (CRL) Widens CliniPrime GMP Suite With New Launch
December 1, 2023 | Tomorrow Investor (Ad)
Why Microsoft Just Placed A Huge Bet On Nuclear
Even with aggressive expansion and acquisition of solar and wind farms, renewable energy isn’t anywhere close to providing the energy that Microsoft demands.
November 17, 2023 | finance.yahoo.com
Chairman of Charles River Laboratories International James Foster Buys 2.3% More Shares
November 17, 2023 | finance.yahoo.com
Charles River Laboratories International Insiders Added US$1.91m Of Stock To Their Holdings
November 13, 2023 | markets.businessinsider.com
Charles River And Aitia Enter Strategic Agreement
November 13, 2023 | finance.yahoo.com
Charles River Laboratories International, Inc.: Reaffirming BUY
November 10, 2023 | finance.yahoo.com
Charles River Laboratories International, Inc. (NYSE:CRL) Q3 2023 Earnings Call Transcript
December 1, 2023 | Wealthpress (Ad)
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
November 9, 2023 | seekingalpha.com
Charles River: Q3 Points To Ongoing Deterioration
November 8, 2023 | msn.com
Charles River Labs Q3 Revenue Jumps 4% Despite Softer Client Spending, Narrows Outlook
November 8, 2023 | finance.yahoo.com
Charles River Laboratories Posts Mixed Q3 Results; Updates 2023 Outlook
November 8, 2023 | seekingalpha.com
Charles River Laboratories International, Inc. 2023 Q3 - Results - Earnings Call Presentation
November 8, 2023 | markets.businessinsider.com
Charles River Laboratories Narrows FY23 Outlook Range; Q3 Results Top Estimates
November 8, 2023 | finance.yahoo.com
Charles River Laboratories Announces Third-Quarter 2023 Results
November 6, 2023 | finance.yahoo.com
Unlocking Q3 Potential of Charles River (CRL): Exploring Wall Street Estimates for Key Metrics
October 11, 2023 | finance.yahoo.com
Charles River Laboratories Achieves 90% Renewable Electricity Globally, Announces Progress on Environmental Goals
October 6, 2023 | seekingalpha.com
Charles River Laboratories: Diving Into The Lab (Rating Upgrade)
September 27, 2023 | finance.yahoo.com
Unveiling the Investment Potential of Charles River Laboratories International Inc (CRL): A ...
September 26, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Charles River Labs (CRL) and Immunovant (IMVT)
September 26, 2023 | msn.com
Charles River (CRL) Opens a RightSource Lab in Stevenage
September 26, 2023 | finance.yahoo.com
Charles River Unveils Lentivation Platform to Expedite LVV-based Gene Therapy Manufacturing
September 25, 2023 | nasdaq.com
TD Cowen Maintains Charles River Laboratories International (CRL) Market Perform Recommendation
September 25, 2023 | finance.yahoo.com
Charles River Announces Opening of RightSourceSM Laboratory, Supporting Stevenage Biocluster
September 22, 2023 | msn.com
Baird Maintains Charles River Laboratories International (CRL) Outperform Recommendation
September 22, 2023 | msn.com
Guggenheim Maintains Charles River Laboratories International (CRL) Buy Recommendation
September 22, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX) and Charles River Labs (CRL)
See More Headlines
Receive CRL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Charles River Laboratories International and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2023
Today
11/30/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/28/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Diagnostics & Research
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
Current Symbol
NYSE:CRL
CUSIP
15986410
CIK
1100682
Web
www.criver.com
Phone
(781) 222-6000
Fax
978-988-5665
Employees
20,000
Year Founded
1947

Price Target and Rating

Average Stock Price Target
$232.54
High Stock Price Target
$275.00
Low Stock Price Target
$203.00
Potential Upside/Downside
+18.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.64
Research Coverage
11 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$9.24
Trailing P/E Ratio
21.33
Forward P/E Ratio
18.65
P/E Growth
2.08
Net Income
$486.23 million
Net Margins
11.27%
Pretax Margin
14.65%
Return on Equity
18.15%
Return on Assets
7.49%

Debt

Debt-to-Equity Ratio
0.76
Current Ratio
1.45
Quick Ratio
1.16

Sales & Book Value

Annual Sales
$3.98 billion
Price / Sales
2.54
Cash Flow
$17.32 per share
Price / Cash Flow
11.38
Book Value
$64.57 per share
Price / Book
3.05

Miscellaneous

Outstanding Shares
51,270,000
Free Float
50,603,000
Market Cap
$10.10 billion
Optionable
Optionable
Beta
1.35

Social Links

Beginner's Guide to Pot Stock Investing Cover
Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report














CRL Stock Analysis - Frequently Asked Questions

Should I buy or sell Charles River Laboratories International stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Charles River Laboratories International in the last twelve months. There are currently 4 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CRL shares.
View CRL analyst ratings or view top-rated stocks.

What is Charles River Laboratories International's stock price target for 2024?

11 Wall Street research analysts have issued 12 month price objectives for Charles River Laboratories International's shares. Their CRL share price targets range from $203.00 to $275.00. On average, they anticipate the company's share price to reach $232.54 in the next year. This suggests a possible upside of 18.0% from the stock's current price.
View analysts price targets for CRL or view top-rated stocks among Wall Street analysts.

How have CRL shares performed in 2023?

Charles River Laboratories International's stock was trading at $217.90 at the beginning of 2023. Since then, CRL shares have decreased by 9.6% and is now trading at $197.08.
View the best growth stocks for 2023 here.

When is Charles River Laboratories International's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024.
View our CRL earnings forecast.

How were Charles River Laboratories International's earnings last quarter?

Charles River Laboratories International, Inc. (NYSE:CRL) released its quarterly earnings results on Wednesday, November, 8th. The medical research company reported $2.72 earnings per share for the quarter, beating analysts' consensus estimates of $2.35 by $0.37. The medical research company had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1 billion. Charles River Laboratories International had a trailing twelve-month return on equity of 18.15% and a net margin of 11.27%. The business's quarterly revenue was up 3.8% on a year-over-year basis. During the same quarter last year, the firm posted $2.63 EPS.
Read the conference call transcript.

What ETFs hold Charles River Laboratories International's stock?

ETFs with the largest weight of Charles River Laboratories International (NYSE:CRL) stock in their portfolio include First Trust NYSE Arca Biotechnology Index Fund (FBT), Future Fund Active ETF (FFND), Future Fund Long/Short ETF (FFLS), Horizon Kinetics Inflation Beneficiaries ETF (INFL), Franklin Genomic Advancements ETF (HELX), VanEck Biotech ETF (BBH), BlackRock Future Innovators ETF (BFTR) and ROBO Global Healthcare Technology and Innovation ETF (HTEC).

What guidance has Charles River Laboratories International issued on next quarter's earnings?

Charles River Laboratories International issued an update on its FY23 earnings guidance on Wednesday, November, 8th. The company provided EPS guidance of $10.50-10.70 for the period, compared to the consensus estimate of $10.54. The company issued revenue guidance of ~$4.08-4.12 billion, compared to the consensus revenue estimate of $4.14 billion.

What is James C. Foster's approval rating as Charles River Laboratories International's CEO?

291 employees have rated Charles River Laboratories International Chief Executive Officer James C. Foster on Glassdoor.com. James C. Foster has an approval rating of 75% among the company's employees.

What other stocks do shareholders of Charles River Laboratories International own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Charles River Laboratories International investors own include NVIDIA (NVDA), Boeing (BA), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA), Salesforce (CRM), Abbott Laboratories (ABT), Mastercard (MA), Intuitive Surgical (ISRG) and Johnson & Johnson (JNJ).

Who are Charles River Laboratories International's major shareholders?

Charles River Laboratories International's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Kayne Anderson Rudnick Investment Management LLC (3.41%), Clearbridge Investments LLC (3.41%), Allspring Global Investments Holdings LLC (2.33%), Ariel Investments LLC (2.08%), Invesco Ltd. (1.81%) and Mackenzie Financial Corp (1.80%). Insiders that own company stock include Birgit Girshick, David Ross Smith, Deborah Turner Kochevar, George Massaro, James C Foster, James C Foster, Joseph W Laplume, Michael Gunnar Knell, Richard F Wallman, Shannon M Parisotto, Victoria L Creamer, William D Barbo and William D Barbo.
View institutional ownership trends.

How do I buy shares of Charles River Laboratories International?

Shares of CRL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does Charles River Laboratories International have any subsidiaries?
The following companies are subsidiares of Charles River Laboratories International: 3313290 Nova Scotia Company, 9904140 Canada Inc., Accugenix Inc., Agilux Laboratories, Argenta Discovery 2009 Limited, Ballardvale C.V., Beijing Vital River Laboratory Animal Technology Co. Ltd., BioFocus DPI (Holdings) Ltd., Biological Laboratories Europe Ltd. ("BioLabs"), Blue Stream Laboratories, Brains On-Line, CRL Dutch Holding Company B.V., CRL Group France, CRL Group International France, CRL Holding Germany GmbH, CRL Holding Netherlands B.V., CRL Safety Assessment Inc., Celsis Group Limited, Celsis International, Celsis International B.V., Celsis International GmbH, Celsis International Limited, Celsis Limited, Cerebricon, Chantest, Charles River Detecção Microbiana e de Endotoxina Participações Ltda, Charles River Discovery Research Services Finland, Charles River Discovery Research Services Germany GmbH, Charles River Discovery Research Services Inc., Charles River Discovery Research Services International Inc., Charles River Discovery Research Services UK Limited, Charles River Endotoxin Microbial Detection Europe SAS, Charles River Endotoxin and Microbial Detection Israel, Charles River Endotoxin and Microbial Detection Singapore Pte. Ltd., Charles River Germany GmbH & Co. KG, Charles River Germany Verwaltungs GmbH, Charles River Holdings LLC, Charles River Laboratories Ashland LLC, Charles River Laboratories Asia Holdings Limited, Charles River Laboratories Australia Pty. Ltd., Charles River Laboratories Belgium SPRL, Charles River Laboratories Cleveland Inc., Charles River Laboratories Copenhagen, Charles River Laboratories Den Bosch B.V., Charles River Laboratories Edinburgh Ltd., Charles River Laboratories España SA, Charles River Laboratories Evreux, Charles River Laboratories France Safety Assessment SAS, Charles River Laboratories France-C.R.L.F. SAS, Charles River Laboratories Germany GmbH, Charles River Laboratories Group, Charles River Laboratories Holding Europe SAS, Charles River Laboratories Holding SAS, Charles River Laboratories Holdings Limited, Charles River Laboratories Hungary, Charles River Laboratories I Delaware Holdings Inc., Charles River Laboratories II Delaware Holdings Inc., Charles River Laboratories Inc., Charles River Laboratories India Private Limited, Charles River Laboratories Ireland Holding Unlimited Company, Charles River Laboratories Ireland Limited, Charles River Laboratories Italia Srl, Charles River Laboratories Japan Inc., Charles River Laboratories Korea, Charles River Laboratories Luxembourg S.a.r.l., Charles River Laboratories Montreal ULC, Charles River Laboratories Poland Sp. Z.o.o., Charles River Laboratories Research Models and Services Germany GmbH, Charles River Laboratories SA France Acquisition SAS, Charles River Laboratories SA France Holdings SAS, Charles River Laboratories SA Japan KK, Charles River Laboratories SA Netherlands Holdings B.V., Charles River Laboratories SA USA Inc., Charles River Laboratories Saint Nazaire, Charles River Laboratories Saint‑Constant S.A., Charles River Microbial Solutions Company (Shanghai) Limited, Charles River Microbial Solutions International Limited, Charles River Nederland B.V., Charles River UK Limited, Charles River ULC, CiToxLAB, Citox Inc., Citoxlab USA LLC, Cognate BioServices, Genetic Models, HemaCare, Inveresk Research, KWS BioTest, KWS BioTest Limited, MPI Research, Molecular Therapeutics, Nastor Investments, NewLab BioQuality AG, Northwest Kinetics, Oncotest, Pathology Associates International Corporation, Piedmont Research Center, Primedica, Retrogenix Limited, River Valley Farms, Saothorlanna Bitheolaiocha Idirnaisiunta Teoranta, Sierra Biomedical, Solvo Biotechnology USA Inc., Solvo Biotechnológiai Zrt, Springborn Laboratories, Sunrise Farms Inc., Systems Pathology Company LLC, Tektagen Inc, Vigene Biosciences Inc., WIL Research, Zhanjiang A&C Biological Ltd., and Zhejiang Vital River Laboratory Animal Technology Co. Ltd..
Read More
This page (NYSE:CRL) was last updated on 12/1/2023 by MarketBeat.com Staff

My Account -